EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Pharmacotherapy for pediatric and adolescent agitation in an inpatient behavioral health unit

Michelle Yang iD, Christine M Rarrick iD, Clint Ross iD

Mental Health Clinician · 2026-06 · 16 (3) · 135-140

DOI: 10.9740/mhc.2026.06.135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mental Health Clinician, 2026-06. Verfasst von Michelle Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: (Corresponding author) Clinical Pharmacy Specialist, The Johns Hopkins Hospital, Baltimore, MD, myang.pharm@gmail.com. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pro re nata (PRN) medications can be administered for the treatment of agitation. Evidence-based recommendations for the pharmacologic treatment of agitation in children and adolescents admitted to a behavioral health unit are limited. The primary objective of this study was to analyze medication use patterns for managing agitation in a pediatric and adolescent inpatient behavioral health unit. The secondary objective was to evaluate the effectiveness and safety of commonly administered PRN medications in this population.

Methods

This retrospective chart review included patients who received a 1-time or PRN medication for agitation while admitted to a pediatric and adolescent behavioral health unit between July 1, 2020, and June 31, 2022. Primary outcomes examined agents administered and the route and rate of concurrent medication administration. Secondary outcomes included administration of subsequent medications, the use of restraint or seclusion as a surrogate marker for effectiveness, and rate of adverse events for safety.

Results

A total of 191 patients were included in the final analysis. There were 1238 doses of 1-time or PRN medication administered for agitation during the study period. Antipsychotics were administered most frequently (661, 53.4%). However, the most commonly administered medications were diphenhydramine (327, 26.4%), lorazepam (235, 19%), and olanzapine (224, 18.1%). Antipsychotic-induced extrapyramidal symptoms (EPS) occurred in 3 instances (0.24%), with all being managed with diphenhydramine.

Discussion

When treating agitation in pediatric and adolescent patients admitted to an inpatient behavioral health unit, antipsychotics were administered most frequently. It appears that most doses were well tolerated, except for EPS in a subset of patients.

Schlagwörter

Stichwörter der Autor:innen

adolescentagitationbehavioral healthinpatientpediatric

Autor:innen und Institutionen

  • (Corresponding author) Clinical Pharmacy Specialist, The Johns Hopkins Hospital, Baltimore, MD, myang.pharm@gmail.com.
  • Clinical Inpatient Manager, Medical University of South Carolina, Charleston, South Carolina.
  • Pharmacy Manager, Medical University of South Carolina, Charleston, South Carolina.

ORCID-Profile: Michelle Yang, Christine M Rarrick, Clint Ross

Zitieren

APA

Yang, M., Rarrick, C. M., & Ross, C. (2026). Pharmacotherapy for pediatric and adolescent agitation in an inpatient behavioral health unit. Mental Health Clinician, 16(3), 135-140. https://doi.org/10.9740/mhc.2026.06.135

Vancouver

Yang M, Rarrick CM, Ross C. Pharmacotherapy for pediatric and adolescent agitation in an inpatient behavioral health unit. Mental Health Clinician. 2026;16(3):135-140. doi:10.9740/mhc.2026.06.135

BibTeX
@article{Yang2026,
  author = {Yang, Michelle and Rarrick, Christine M and Ross, Clint},
  title = {Pharmacotherapy for pediatric and adolescent agitation in an inpatient behavioral health unit},
  journal = {Mental Health Clinician},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {135--140},
  doi = {10.9740/mhc.2026.06.135}
}
Kostenlos starten →